Cover & TOC
Document type
Document record
Source: BMČ - články
Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases / K. Abd-Elaziz, M. Jesenak, M. Vasakova, Z. Diamant,
Abd-Elaziz, Khalid
Department of Clinical Pharmacology, QPS-Netherlands, Groningen, The Netherlands.

Jesenak, Milos
Department of Pediatrics. Department of Pulmonology and Physiology. Department of Clinical Immunology and Allergology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.

Vasakova, Martina
Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.

Diamant, Zuzana
Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. Dept of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden. Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Cited source
Current opinion in pulmonary medicine. 2021, roč. 27, č. 1, s. 54-60. ISSN: 1070-5287; 1531-6971 (elektronická verze).
Date of issue
Spojené státy americké
Document type
Pubmed ID
Record number
Persistent link
MESH descriptor
COVID-19 (farmakoterapie, enzymologie, etiologie, patofyziologie)
bronchiální astma (farmakoterapie, enzymologie, etiologie, patofyziologie)
biologické markery (metabolismus)
chronická obstrukční plicní nemoc (farmakoterapie, enzymologie, etiologie, patofyziologie)
matrixová metaloproteinasa 12 (metabolismus)
idiopatická plicní fibróza (farmakoterapie, enzymologie, etiologie, patofyziologie)
inhibitory matrixových metaloproteinas (terapeutické užití)
English Abstract
PURPOSE OF REVIEW: Matrix metalloproteinases (MMPs) are a family of over 20 zinc-dependent proteases with different biological and pathological activities, and many have been implicated in several diseases. Although nonselective MMP inhibitors are known to induce serious side-effects, targeting individual MMPs may offer a safer therapeutic potential for several diseases. Hence, we provide a concise overview on MMP-12, given its association with pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and other progressive pulmonary fibrosis (PPF), which may also occur in coronavirus disease 2019. RECENT FINDINGS: In asthma, COPD, and PPF, increased MMP-12 levels have been associated with inflammation and/or structural changes within the lungs and negatively correlated with functional parameters. Increased pulmonary MMP-12 levels and MMP-12 gene expression have been related to disease severity in asthma and COPD. Targeting MMP-12 showed potential in animal models of pulmonary diseases but human data are still very scarce. SUMMARY: Although there may be a potential role of MMP-12 in asthma, COPD and PPF, several pathophysiological aspects await elucidation. Targeting MMP-12 may provide further insights into MMP-12 related mechanisms and how this translates into clinical outcomes; this warrants further research.
Further actions